Spain cuts drug funding delays as European pharma investment yields sixfold returns

Spanish Health Minister Mónica García said the country needs another legislative term to strengthen its role as a European bio‑pharmaceutical hub, emphasizing Spain’s robust universal system, high number of clinical trials and stable regulatory capacity.

A study by the European Federation of Pharmaceutical Industries and Associations (EFPIA) found that €11.67 billion invested in new medicines across Europe between 2014 and 2024 generated a total impact of about €66 billion – roughly six times the outlay – including €9 billion in direct hospital savings, 38 billion euros in labour productivity and a reduction of 1.83 million years of life lost before age 85.

Spain’s Ministry of Health reported that the median time for a new drug to move from EU authorization to public financing fell to 474 days, a 70‑day improvement over three years. Of the 221 innovative medicines authorized in the EU, 84.6 % were registered in Spain and 76.5 % of those received public funding, giving an overall financing rate of 64.7 %. The early‑access scheme for special situations (MSE) helped 55.2 % of the drugs reach patients sooner, especially for rare‑disease treatments.